Bristol-Myers Squibb presents Opdivo data at ASCO
pharmafile | June 6, 2016 | News story | Research and Development, Sales and Marketing | ASCO, Bristol-Myers Squibb, opdivo
Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications at the annual meeting of the American Society of Clinical Oncology (ASCO).
Hailed as a “wonder drug” and potential blockbuster for BMS, Opdivo has secured a range of approvals in multiple cancer indications and these latest results presented at the ASCO suggest its efficacy across further forms of the disease.
In early stage trials, Opdivo demonstrated effectiveness in combination with Yervoy, achieving clinically meaningful responses in first-line advanced non-small cell lung cancer. Jean Viallet, global clinical research lead in oncology at BMS, comments: “We find these Opdivo and Yervoy combination regimen results in first-line advanced non-small cell lung cancer compelling. These data reinforce our approach to identify an optimised combination dosing schedule for further study in patients with advanced non-small cell lung cancer.”
Yervoy features again in the mid-stage CheckMate -142 trial evaluating Opdivo as both monotherapy and combination therapy for MSI-high metastatic colorectal cancer. In the trial, six-month progression-free survival rates were 45.9% for Opdivo alone, and 66.6% for the combination of the two drugs. David Feltquate, development lead in oncology life cycle management at BMS, says: “We are encouraged by the preliminary results from our ongoing efforts to evaluate the full potential of this combination regimen across a range of malignancies.”
Furthermore, the drug achieved what BMS refers to as “promising response rates” in a Phase I/II trial for advanced bladder cancer treatment. The trial met its primary endpoint of objective response rate, which was 24.4%, while patients had an overall survival rate after one year of 45.6%. Viallet adds: “We are excited to present for the first time results for Opdivo in previously treated metastatic urothelial cancer. We are encouraged by the response rates and overall survival data observed with Opdivo in CheckMate -032, which supports the ongoing Phase II study in this cancer.”
Sean Murray
Related Content
ISA Pharmaceuticals highlights positive clinical data at ASCO
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American …
NICE approves first treatment for obstructive HCM for NHS use
The National Institute for Health and Care Excellence (NICE) has announced that it has approved …
AstraZeneca shares oncology data at ASCO 2023
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …
